[
  {
    "ts": null,
    "headline": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
    "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
    "url": "https://finnhub.io/api/news?id=06215b717963945c9963b8a712e672df556fb394ab6ba879e3642747690c939a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767975542,
      "headline": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
      "id": 138052209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
      "url": "https://finnhub.io/api/news?id=06215b717963945c9963b8a712e672df556fb394ab6ba879e3642747690c939a"
    }
  },
  {
    "ts": null,
    "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
    "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
    "url": "https://finnhub.io/api/news?id=8a744dad378981948ddd9bbf5a218db486800ed8d38efd33667ffd0ec67117ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767973860,
      "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
      "id": 138052210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
      "url": "https://finnhub.io/api/news?id=8a744dad378981948ddd9bbf5a218db486800ed8d38efd33667ffd0ec67117ca"
    }
  },
  {
    "ts": null,
    "headline": "BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?",
    "summary": "BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure",
    "url": "https://finnhub.io/api/news?id=e0a75d6d7d92c1cc14e1481898b4cb2eaee811fcb3ac631a14336148bb1287ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767968160,
      "headline": "BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?",
      "id": 138046679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure",
      "url": "https://finnhub.io/api/news?id=e0a75d6d7d92c1cc14e1481898b4cb2eaee811fcb3ac631a14336148bb1287ae"
    }
  },
  {
    "ts": null,
    "headline": "Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of Directors",
    "summary": "CAMBRIDGE, England, January 09, 2026--Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced Katerina Leftheris, Ph.D. has joined its Board of Directors. Katerina’s appointment as a Director forms part of the Company’s ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform.",
    "url": "https://finnhub.io/api/news?id=9b7f2ad57bd0f9d7f02d30c19303113cfe9c1b179cccddbfe0cb724eccfae6ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767967800,
      "headline": "Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of Directors",
      "id": 138046745,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, England, January 09, 2026--Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced Katerina Leftheris, Ph.D. has joined its Board of Directors. Katerina’s appointment as a Director forms part of the Company’s ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform.",
      "url": "https://finnhub.io/api/news?id=9b7f2ad57bd0f9d7f02d30c19303113cfe9c1b179cccddbfe0cb724eccfae6ab"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: What to expect from pharma at the JPM conference",
    "summary": "At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.",
    "url": "https://finnhub.io/api/news?id=b176745a81fadd629d60d2032e94bcf615335731dd1a1757a1b83c37313be307",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767963421,
      "headline": "Healthy Returns: What to expect from pharma at the JPM conference",
      "id": 138057238,
      "image": "https://image.cnbcfm.com/api/v1/image/108222520-17624504352025-11-06t173326z_182594845_rc24rhaozaeo_rtrmadp_0_usa-trump.jpeg?v=1767995336&w=1920&h=1080",
      "related": "BMY",
      "source": "CNBC",
      "summary": "At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.",
      "url": "https://finnhub.io/api/news?id=b176745a81fadd629d60d2032e94bcf615335731dd1a1757a1b83c37313be307"
    }
  },
  {
    "ts": null,
    "headline": "J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts",
    "summary": "The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.",
    "url": "https://finnhub.io/api/news?id=d54018c88b87e3d0d35e24ac04c699e68ebb10724d1fa2df4c3d059d2427aae1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767961410,
      "headline": "J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts",
      "id": 138045475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.",
      "url": "https://finnhub.io/api/news?id=d54018c88b87e3d0d35e24ac04c699e68ebb10724d1fa2df4c3d059d2427aae1"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: Is There Life After Broadcom?",
    "summary": "The Schwab U.S. Dividend Equity ETF remains an excellent choice for income-seeking investors, even net of its recent underperformance. Learn more about SCHD ETF here.",
    "url": "https://finnhub.io/api/news?id=634b57c666b87d27f72166b5949ae6f768daae34adb6e536ee655f689485aefe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767948300,
      "headline": "SCHD: Is There Life After Broadcom?",
      "id": 138045626,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1193973091/image_1193973091.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "The Schwab U.S. Dividend Equity ETF remains an excellent choice for income-seeking investors, even net of its recent underperformance. Learn more about SCHD ETF here.",
      "url": "https://finnhub.io/api/news?id=634b57c666b87d27f72166b5949ae6f768daae34adb6e536ee655f689485aefe"
    }
  }
]